MapLight Therapeutics Reports Positive Phase 2 Results for Schizophrenia Treatment ML-007C-MA

MapLight Therapeutics announced positive topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA, an oral M1/M4 muscarinic agonist, in adults with an acute exacerbation of schizophrenia. The trial met its primary endpoint, with the 210/3 mg twice-daily dose showing a statistically significant and clinically meaningful reduction in Positive and Negative Syndrome Scale (PANSS) total score compared to placebo at Week 5. The company plans to engage with the FDA for an End-of-Phase 2 meeting.